Loading…
LMX is a brand name for Lidocaine (also known as Lignocaine). The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Local anaesthetic for topical use to produce surface anaesthesia of the skin prior to: - venous cannulation or venipuncture - administration of painful topical treatments on larger surface areas of intact skin where use of a topical anaesthetic is appropriate.
Verbatim from this product's MHRA label. Tap a section to expand.
For cutaneous use only. 25cm2) area where venous cannulation or venipuncture will occur. No more than 1g of cream should be applied to infants below the age of 1 year. 5cm from the 30g tube. The cream should remain undisturbed and the area can be covered with an occlusive dressing to prevent disturbance or interference by the patient or other external factors.
Adequate anaesthesia should be obtained after 30 minutes, but the LMX4 Cream may be applied for up to 5 hours under a dressing. Prior to starting the procedure, the LMX4 Cream should be removed using a clean gauze swab and the site for venous cannulation or venipuncture prepared in the usual manner.
The procedure should be initiated shortly after the cream has been removed. Maximum application time for 1 month up to 3 month infant should not exceed 60 minutes. Maximum application time for 3 month up to 12 month infant should not exceed 4 hours.
Maximum application for 12 month infant – adult should not exceed 5 hours. LMX4 is not recommended for use in infants under one month of age.
Painful topical treatments on larger surface areas of intact skin:
Adults, including the elderly. 5g to 2g LMX4 /10cm2 skin to be treated, or multiples thereof, up to a maximum area of 900cm2. Apply until response is achieved, which is generally for between 30 to 60 minutes in clinical studies. Typical estimated larger quantities would be 30g-40g/200cm2 (approximately 10cm x 20cm, or covering a face), 45g-60g/300cm2 (approximately 10cm x 30cm or covering an arm), or 135g-180g/900cm2 (approximately 30cm x 30cm, or covering a torso or back).
Indirect evidence has shown that successive applications of lidocaine-based topical treatments can lead to systemic accumulation of lidocaine. LMX4 must therefore not be reapplied for 12 hours following its removal, giving a maximum of 2 doses in any 24 hour period.
The LMX4 cream should be applied evenly at the specified dosage with a uniform thickness across the area where the topical treatment will occur. Measures may be taken to ensure the cream remains undisturbed until adequate analgesia has been achieved.
Prior to starting the procedure, the LMX4 Cream should be removed using a clean gauze swab and the site for topical treatment prepared in the usual manner. The procedure should be initiated shortly after the cream has been removed. Use of LMX4 is not recommended for this indication in patients below 18 years of age.
Common side effects (>1/100) can include irritation, redness, itching, or rash. In rare cases local anaesthetics have been associated with allergic reactions including anaphylactic shock. Corneal irritation after accidental eye exposure.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
For external use only. Avoid contact with eyes. Do not apply to irritated skin or if excessive irritation develops. If condition worsens, or if symptoms persist unaltered for more than seven days or clear up and occur again within only a few days, discontinue use of this product and consult a doctor.
Do not use in large quantities over raw or blistered areas. LMX4 contains 75mg propylene glycol in each 1g. Propylene glycol my cause skin irritation. Because this medicine contains propylene glycol, do not use it on open wounds or large areas of broken or damaged skin (such as burns) without checking with your doctor or pharmacist.
Do not use on infants below one month. LMX4 contains 15mg benzyl alcohol in each 1g. Benzyl alcohol may cause allergic reactions or mild local irritation. 5mg polysorbate 80 in each 1g. Polysorbates may cause allergic reactions. LMX4 has not been applied to wounds, mucous membranes or in areas of atopic dermatitis as there are no clinical data in relation to these.
Anaesthetic efficacy during the heel lancing of neonates has not been studied. Application of lidocaine to larger areas or for longer times than those recommended could result in sufficient absorption of lidocaine resulting in serious adverse effects.
Studies in laboratory animals (guinea pigs) have shown that lidocaine has an ototoxic effect when instilled into the middle ear. In these same studies, animals exposed to lidocaine in the external auditory canal only showed no abnormality.
Lidocaine should not be used in any clinical situation in which its penetration or migration beyond the tympanic membrane into the middle ear is possible. Dermal application of lidocaine may cause transient local blanching followed by transient erythema.
PRECAUTIONS General:
Repeated doses of lidocaine may increase blood levels of lidocaine. Lidocaine should be used with caution in patients who may be more sensitive to the systemic effects of lidocaine including acutely ill, debilitated, or elderly patients.
1.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Lidocaine in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Lidocaine coming in contact with the eye should be avoided because animal studies have demonstrated severe eye irritation. Also the loss of protective reflexes can permit corneal irritation and potential abrasion. Absorption of lidocaine in conjunctival tissues has not been determined.
If eye contact occurs, immediately wash out the eye with water or saline and protect the eye until sensation returns. ) have not shown cross sensitivity to lidocaine; however, lidocaine should be used with caution in patients with a history of drug sensitivities, especially if the etiologic agent is uncertain.
Patients with severe hepatic disease, because of their inability to metabolize local anaesthetics normally, are at greater risk of developing toxic plasma concentrations of lidocaine. When lidocaine is used, the patient should be aware that the production of dermal analgesia may be accompanied by the block of all sensations in the treated skin.
For this reason, the patient should avoid inadvertent trauma to the treated area by scratching, rubbing, or exposure to extreme hot or cold temperatures until complete sensation has returned. 5%. For this reason, the results of intra-cutaneous injections of live vaccines (such as BCG vaccination) should be monitored.
g. amiodarone) should be carefully monitored and ECG monitoring considered as cardiac effects may be additive.